Sidoti & Company, LLC has released the presentation schedule and weblinks for its two-day August Micro-Cap Conference taking place Wednesday and Thursday, August 17-18, 2022. The links can also be found at www.sidoticonference.com/events.
| |||
Presentation Agenda | |||
Wednesday, August 17th, 2022 (Day 1) | |||
8:30-9:00 | |||
9:15-9:45 | |||
10:00-10:30 | ***** | ||
10:45-11:15 | |||
11:30-12:00 | |||
12:15-12:45 | |||
1:00-1:30 | |||
1:45-2:15 | |||
2:30-3:00 | ***** | ||
3:15-3:45 | ***** | ||
4:00-4:30 | ***** | ||
1x1s Only | Gulf Island Fabrication (GIFI) | Kelly Services (KELYA) | |
| |||
Thursday, August 18th, 2022 (Day 2) | |||
9:15-9:45 | |||
10:00-10:30 | |||
10:45-11:15 | |||
11:30-12:00 | |||
12:15-12:45 | |||
1:00-1:30 | |||
1x1s Only | American Woodmark (AMWD) | Paysign, Inc. (PAYS | Wireless Telecom Group (WTT) |
About Sidoti
For over two decades, Sidoti has been a premier provider of independent securities research focused specifically on Small Cap and Micro-Cap companies and the institutions that invest their securities, with most of our coverage in the $50 million to $3 billion market cap range. Our approach affords companies and institutional clients a combination of high-quality research, a Small Cap and Micro-Cap focused nationwide sales effort, and broad access to corporate management teams. We serve 500+ institutional clients in the U.S. and Canada, including many leading institutional managers. Sidoti promotes meaningful interaction between issuers and investors in the Small Cap and Micro-Cap space through a series of investor conferences (www.sidoti.com/events) we host each year.
CONTACT
Sidoti Events Team
212-453-7031
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.85 |
| Daily Change: | 0.18 6.74 |
| Daily Volume: | 143,252 |
| Market Cap: | US$117.080M |
May 13, 2025 February 14, 2025 December 23, 2024 November 13, 2024 September 25, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
